Macrolide antibiotics such as erythromycin have long been used for treatment of upper and lower respiratory infections against Gram-positive bacteria. Such antibiotics have the advantage of a relatively small number of side effects.
Degradation of erythromycin in the acidic environment of the stomach yields 8,9-anhydroerythromycin A 6,9-hemiketal, which causes gastrointestinal discomfort.^The analogs clarithromycin,2) azithromycin3) and roxithromycin4) were developed to avoid formation of such by-products and improve pharmacokinetic properties of erythromycin. 5)
A more recent problem with erythromycin A and subsequent derivatives is the increasing incidence of resistance. Anew class of macrolides knownas ketolides show promising activity against erythromycin A-resistant microorganisms. Ketolides have been synthesized by replacing the 3-cladinosyl group with a carbonyl and addition of an TV-alkylaromatic substituted C1 1-C12 cyclic carbamate which enhances ribosomal binding.6) Synthesis and biological evaluation of a number of different ketolides with various aromatic substituents has proven useful in pp.278 -284 optimizing the effectiveness of such compounds. However, the effects of substitution at the 13-position of the erythromycin A derivatives on antibacterial activity have not been thoroughly investigated. Technology developed by Khosla and co-workers allows manipulation of the polyketide synthases that generate a number of natural products.7) This technique has been applied to make erythromycin analogues with different substituents at the 13 position such as 14,15-dehydroerythromycin.8) We report here the synthesis of a 14,15-dehydroketolide and describe unexpected effects of the 13-substitution on the tautomeric equilibria of erythromycin A. tautomeric differences between the 13-ethyl and the 13-vinyl macrolides required the development of a novel synthetic strategy.
Results and Discussion
Both 6-0-methylerythromycin A (la) and 14,15-dehydro-6-O-methylerythromycin (lb) were prepared by alkylation of the corresponding erythromycins ( Fig. 1 ).9)
Acid hydrolysis of the cladinose followed by acetylation of the 2' position gave intermediate 3. Moffat oxidation of 3a provided the desired ketone 4a along with a minor amount (3-5%) of a doubly-oxidized product, assumed to be 5a
(vide infra). Applying identical reaction conditions to 3b, however, resulted in unacceptable levels of over-oxidation.
Upon complete consumption of 3b, the products 4b and 5b
were detected in approximately equal amounts. Mass spectrometric analysis of partial reactions indicated a 1 : 2 : 1 mixture of starting material 3b, product 4b, and the doubly-oxidized product 5b, suggesting that it would not be possible to control the formation of 5b and still achieve acceptable levels of conversion. Anefficient separation of 4b and 5b could not be achieved, so the mixture was carried forward. Treatment of a mix of 4b and 5b with methanesulfonyl chloride and subsequently with diazabicycloundecene provided 7b and 8b, which could be separated and fully characterized. Structural determination The 9-keto form (A) is in equilibrium with the 9,12-hemiketal (B) and 6,9-hemiketal (C) forms.
of 8b corroborated the suspected structure of the doubly oxidized compound 5b. The observed difference in reactivity between 3a and 3b strongly suggests underlying conformational or tautomeric differences between the two molecules. Evidence for this hypothesis was obtained through NMR studies of the corresponding erythromycins. Erythromycin A has been shown to exist as a mixture of 9-keto-(9A), 9,12-hemiketal-(9B), and 6,9-hemiketal-(9C) forms, with the ratio of tautomers depending strongly upon the solvent (Fig. 2) .10) The ratio of9A to 9B is approximately 30 : 1 in CDC13 but 6 : 1 in CD3OD. Tautomer 9C is very minor (25 %) in both media. Examination of the NMRspectra of 14,15-dehydroerythromycin A (10A) revealed similar tautomeric forms, although with markedly different ratios of the tautomers. The ratio of10A to 10B is 9 : 1 in CDC13 and 1 : 1 in CD3OD. As with erythromycin, IOC remains minor in both media. Tautomer 10B was clearly identified as the major hemiketal in CD3ODby NMR.The 9-keto tautomer 10A shows resonances for C9, C12, and C6 at <5 219.9, 75.1, and 74.3, respectively, whereas the major hemiketal tautomer shows these signals at <5 107.0, 82.0, and 74.1, consistent with the 9,12-hemiketal 10B. Assignments were made using HSQCand HMBC experiments, and agree with values reported for the tautomers of 9.10)
Formation of the 9,12-hemiketal is thus more favored when the 13-group is vinyl than when it is ethyl. The cause of this is uncertain, although a reduced steric demand for the vinyl group in the 9,12-hemiketal is a likely contributing factor. Formation of 9B results in a synpentane-type interaction between the 14-CH2 and 1 1-OH groups, which is lessened in 10B due to the planarity of the 14-CH. We hypothesize that formation of the 9,12-hemiketal and concomitant exposure of the normally unreactive 1 1-OHmay account for the different reactivities of3a and 3b towards oxidation.
To avoid these difficulties, we developed a synthetic sequence in which the 10,1 1-alkene is introduced prior to the oxidation step (Fig. 3) . Following protection of the 2'-hydroxyl of 1, mesylation provides the 4",l l-0-mesylate 12 and the 1 1-0-mesyl group is eliminated by treatment with base to yield 13. The 4-O-mesylcladinose is hydrolyzed, and the resulting 3-hydroxyl is oxidized to provide the ketolide 15. When applied to lb, this sequence provided 15b in 28% overall yield, substantially improved over the 14% yield obtained using the sequence in Figure 1 . Hydrolysis of the 4-O-mesylated-cladinose from 13 requires harsher conditions than observed with 1, yet provides 14 in good yield. This approach was also successful with R=CH3CH2, converting la into ketolide 15a in 35% overall yield compared with 25% yield obtained using the procedure of Figure 1 .
These results demonstrate an unexpected effect of the 1 3-substituent on the tautomeric equilibria and consequent reactivity of erythromycin A. An alternate route for the preparation of the ketolides from clarithromycin and its analogs was developed to compensate for these effects which resulted in a higher overall yield and ease of 
Materials and Methods

General Experimental Procedures 14,15-Dehydroerythromycin
A was produced by fermentation by precursor-directed biosynthesis.8) All other materials were reagent grade and used as provided unless otherwise stated. All reactions were performed under N2 atmosphere. Columnchromatography was performed with Merck 60 230-400 mesh silica gel. Thin layer chromatography was performed on pre-coated glass with silica gel 60 and the spots were visualized by vanillin followed by heating.
lH NMR (400MHz) and 13C NMR (100MHz) spectra were recorded in CDC13solution at 300K (Bruker DRX-400 spectrometer). Mass spectra were obtained using electrospray ionization with a PE/Sciex API-100LC mass spectrometer equipped with a Turbo Ion Spray source. (C) 2 ' ,4"-bis-O-Trimethylsilyl-14, 1 5-dehydroerythromycin
A solution of IB (80mg, 0.090mmol) in CH2C12 (0.90 ml) was treated with 1-trimethylsilylimidazole (36 /il, 0.24 mmol) and chlorotrimethylsilane (20^1, 0. 153 mmol). The solution was stirred at ambient temperature for 10 minutes. The reaction mixture was diluted with 50 ml of CH2C12and washed with 1 n NaOHsolution. The aqueous layer was washed with CH2C12(3 X60 ml). The organic extracts were combined, dried, and evaporated to give the desired product (E) 6-O-methyl-1 4, 1 5-dehydroerythromycin A 9-oxime (IE) A solution of ID (344mg, 0.329mmol) in 2 : 1 CH3CN/ H2O (5.06ml) and AcOH (1.83 ml, 31.9 mmol) was stirred at ambient temperature for 8hours. The reaction was adjusted to pH 12 with In NaOHand extracted with MAR. 2001 CH2C12 (4X50ml).
The organic extracts were combined, washed with brine, and dried to give IE as a white solid (245mg 1.16.8, 106.7, 88.5, 79.0, 78.1, 74.6,-74.2, 70.6, 70.2, 69.6, 65.7, 49.5, 45.5, 44.3, 40.2, 38.7, 37.7, 35.8, 28.1, 21.2, 18.8, 17.7, 16.4, 14.6, 12 .4,
A mixture of 2b (llOmg, 0.187mmol) in 1.34ml of CH2C12, potassium carbonate (77mg, 0.561 mmol), and acetic anhydride (26^1, 0.281 mmol) was stirred for 15 hours. The reaction was diluted with CH2C12and washed with NaHCO3. The aqueous layer was extracted with CH2C12(5X50 ml) and the organic extracts were combined and dried to give 3b as a white solid (100mg, 85%). MS m/z 630.6 (M+H)+.
Oxidation of3b (4b+5b)
A solution of pyridinium trifluoroacetate (107 mg, 0.553 to gave 20 mg (70%) ofa 3 :2 mixture of7b and 8b as a white solid. The products were purified by HPLC (C18, .8,203.1, 169.7, 168.2, 141.4, 139.6, 131.5, 120.2, 101.9, 80.7, 80.4, 78.7, 72.6, 71.5, 69.1, 63.4, 51.2, 50.5, 47.1, 40.6, 39.9, 30.4, 29.3, 22.7, 22.2, 21.3, 21.0, 18.6, 14.4, 14.0, 13.6 .MSm/z611 (M+H)+.
The 2'-<9-acetate was lost from 8b during purification. (14.6ml) was stirred with the Dess-Martin periodinane (427mg) for 1 hours. The mix was diluted with CH2C12, satd aq NaHCO3was added, and the product was extracted with CH2C12 (4X40 ml). The combined extract was dried in vacuo. Column chromatography (90 ; 9 : 1 toluene/Me2CO/
